Answers are grounded in this paper and cite their sources.
This analysis examines hydatidiform mole types and beta-hCG levels in women with gestational trophoblastic disease, indicating diagnostic challenges ahead.
Background Gestational trophoblastic disease (GTD) encompasses a group of diseases diagnosed during pregnancy. Hydatidiform mole (HM) refers to premalignant disorders where villi contain excess paternal genetic material, either due to complete absence of maternal material (complete molar pregnancy) or excess paternal material combined with maternal material (partial molar pregnancy). Complete mole (CHM) has a higher malignant potential than partial mole (PHM). Gestational trophoblastic neoplasia includes invasive mole, choriocarcinoma, placental site trophoblastic tumor (PSTT), and epithelioid trophoblastic tumor. Diagnosing GTD can be difficult with curettage material, requiring correlation with serum beta-hCG levels and radiological findings. CHM typically shows severe villous swelling resembling a bunch of grapes and usually lacks an embryo, while PHM has less swelling and usually contains an embryo. If CHM or PHM invades the myometrium, it is classified as invasive mole. After HM, full-term pregnancy, miscarriage, or ectopic pregnancy may follow. Choriocarcinoma may arise after a miscarriage or full-term pregnancy and appear years later with metastases, elevated beta-hCG levels, and normal pelvic ultrasound. Pathological diagnosis may not always distinguish PHM from CHM, with reports often stating HM without specifying whether it is complete or partial. This study aims to analyze cases identified by pathological anatomy (PA), types of CHM, PHM, (histologically undefined hydatidiform mole) HUHM, and beta-hCG levels before and 30 days after PA. Methods The authors analyzed of 2019 to 2024, 316 cases of women who had undergone pathological examination (PA) of HM and beta-hCG levels before and after 30 days of the procedure. The ages ranged from 19 to 34 years. Our sample belongs to the database of a large laboratory headquartered in São Paulo, Brazil. Statistics: The chi-square test of independence was used to compare the frequency of each type of mole between years. Pearson*s residuals were used, and the nonparametric Kruskal-Wallis test was used to compare beta-hCG values, ages, and mole volume between the different types of moles. Results When comparing the types of HM that were characterized, the authors found a statistically significant difference (p=0.001) between them. In 2019 was found: the highest frequency in CHM (33%) ( n= 85) and in the other years (2020 – 2024) the highest percentages were in HUHM,n=146,(37%) except in 2024, when PHM, n= 85, presented the highest frequency (30%). The mean levels of beta-hCG before the procedure ranged from 149.0 to 186.0 mIU / mL (p = 0.33) among the three types of HM and after 30 days from 16.47 to 18.07 mIU / mL (p = 0.84) there were not statistical difference between the types and neither in the two phases. Conclusion According to this data, the most frequent HM type was HUHM during these 6 years. Fact suggests research into molecular genetic testing. The importance of diagnosing GTD diseases, including the diagnosis of HM, is fundamental for treatment. The use of chemotherapy has dramatically improved the prognosis of these lesions. All patients with this rare disease need to be registered with the national gestational trophoblastic disease service.
No takes yet. Share an insight, caveat, or question.
Feres et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: